nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP2E1—prostate cancer	0.165	0.503	CbGaD
Dexmedetomidine—CYP1A1—prostate cancer	0.162	0.497	CbGaD
Dexmedetomidine—CYP1A1—Flutamide—prostate cancer	0.065	0.185	CbGbCtD
Dexmedetomidine—CYP1A1—Estrone—prostate cancer	0.047	0.134	CbGbCtD
Dexmedetomidine—CYP2E1—Estrone—prostate cancer	0.0363	0.103	CbGbCtD
Dexmedetomidine—CYP1A2—Flutamide—prostate cancer	0.029	0.0826	CbGbCtD
Dexmedetomidine—CYP2D6—Bicalutamide—prostate cancer	0.0289	0.0822	CbGbCtD
Dexmedetomidine—CYP1A1—Estradiol—prostate cancer	0.027	0.0768	CbGbCtD
Dexmedetomidine—CYP2D6—Abiraterone—prostate cancer	0.0239	0.0681	CbGbCtD
Dexmedetomidine—CYP2E1—Mitoxantrone—prostate cancer	0.0216	0.0614	CbGbCtD
Dexmedetomidine—ADRA1B—vas deferens—prostate cancer	0.0215	0.45	CbGeAlD
Dexmedetomidine—CYP1A2—Estrone—prostate cancer	0.021	0.0597	CbGbCtD
Dexmedetomidine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0137	0.0391	CbGbCtD
Dexmedetomidine—CYP2E1—Etoposide—prostate cancer	0.0136	0.0387	CbGbCtD
Dexmedetomidine—CYP1A2—Estradiol—prostate cancer	0.0121	0.0343	CbGbCtD
Dexmedetomidine—CYP1A2—Etoposide—prostate cancer	0.00787	0.0224	CbGbCtD
Dexmedetomidine—CYP2D6—Doxorubicin—prostate cancer	0.00443	0.0126	CbGbCtD
Dexmedetomidine—CYP1A2—urine—prostate cancer	0.00248	0.052	CbGeAlD
Dexmedetomidine—CYP2E1—urine—prostate cancer	0.00223	0.0468	CbGeAlD
Dexmedetomidine—ADRA1D—prostate gland—prostate cancer	0.00188	0.0393	CbGeAlD
Dexmedetomidine—CYP2D6—urine—prostate cancer	0.00177	0.037	CbGeAlD
Dexmedetomidine—ADRA1D—epithelium—prostate cancer	0.00138	0.0289	CbGeAlD
Dexmedetomidine—ADRA1B—renal system—prostate cancer	0.00131	0.0274	CbGeAlD
Dexmedetomidine—ADRA1D—urethra—prostate cancer	0.00126	0.0263	CbGeAlD
Dexmedetomidine—ADRA2C—prostate gland—prostate cancer	0.00103	0.0215	CbGeAlD
Dexmedetomidine—ADRA2C—seminal vesicle—prostate cancer	0.000869	0.0182	CbGeAlD
Dexmedetomidine—ADRA2A—prostate gland—prostate cancer	0.00082	0.0172	CbGeAlD
Dexmedetomidine—CYP2E1—prostate gland—prostate cancer	0.000802	0.0168	CbGeAlD
Dexmedetomidine—ADRA2C—renal system—prostate cancer	0.0007	0.0147	CbGeAlD
Dexmedetomidine—ADRA2A—seminal vesicle—prostate cancer	0.000693	0.0145	CbGeAlD
Dexmedetomidine—ADRA2C—urethra—prostate cancer	0.000688	0.0144	CbGeAlD
Dexmedetomidine—CYP2E1—seminal vesicle—prostate cancer	0.000678	0.0142	CbGeAlD
Dexmedetomidine—CYP1A1—epithelium—prostate cancer	0.000646	0.0135	CbGeAlD
Dexmedetomidine—CYP1A2—renal system—prostate cancer	0.000608	0.0127	CbGeAlD
Dexmedetomidine—CYP1A1—renal system—prostate cancer	0.000599	0.0125	CbGeAlD
Dexmedetomidine—CYP1A1—urethra—prostate cancer	0.000589	0.0123	CbGeAlD
Dexmedetomidine—ADRA2A—urethra—prostate cancer	0.000549	0.0115	CbGeAlD
Dexmedetomidine—CYP2E1—renal system—prostate cancer	0.000547	0.0114	CbGeAlD
Dexmedetomidine—CYP2E1—urethra—prostate cancer	0.000537	0.0112	CbGeAlD
Dexmedetomidine—SLC6A2—testis—prostate cancer	0.000511	0.0107	CbGeAlD
Dexmedetomidine—ADRA2C—testis—prostate cancer	0.000453	0.00947	CbGeAlD
Dexmedetomidine—CYP2D6—renal system—prostate cancer	0.000433	0.00906	CbGeAlD
Dexmedetomidine—SLC6A2—lymph node—prostate cancer	0.00037	0.00775	CbGeAlD
Dexmedetomidine—ADRA2A—testis—prostate cancer	0.000361	0.00756	CbGeAlD
Dexmedetomidine—CYP2E1—testis—prostate cancer	0.000353	0.00739	CbGeAlD
Dexmedetomidine—ADRA2C—lymph node—prostate cancer	0.000328	0.00687	CbGeAlD
Dexmedetomidine—CYP1A1—lymph node—prostate cancer	0.000281	0.00588	CbGeAlD
Dexmedetomidine—CYP2D6—testis—prostate cancer	0.00028	0.00585	CbGeAlD
Dexmedetomidine—ADRA2A—lymph node—prostate cancer	0.000262	0.00548	CbGeAlD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—prostate cancer	8.32e-05	0.000504	CcSEcCtD
Dexmedetomidine—Dizziness—Goserelin—prostate cancer	8.28e-05	0.000502	CcSEcCtD
Dexmedetomidine—Dyspnoea—Mitoxantrone—prostate cancer	8.25e-05	0.0005	CcSEcCtD
Dexmedetomidine—Somnolence—Mitoxantrone—prostate cancer	8.23e-05	0.000498	CcSEcCtD
Dexmedetomidine—Dizziness—Conjugated Estrogens—prostate cancer	8.21e-05	0.000497	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Estradiol—prostate cancer	8.18e-05	0.000496	CcSEcCtD
Dexmedetomidine—Convulsion—Etoposide—prostate cancer	8.17e-05	0.000495	CcSEcCtD
Dexmedetomidine—Angiopathy—Docetaxel—prostate cancer	8.17e-05	0.000495	CcSEcCtD
Dexmedetomidine—Hypertension—Etoposide—prostate cancer	8.14e-05	0.000493	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Estradiol—prostate cancer	8.12e-05	0.000492	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Docetaxel—prostate cancer	8.12e-05	0.000491	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Capecitabine—prostate cancer	8.09e-05	0.00049	CcSEcCtD
Dexmedetomidine—Chills—Docetaxel—prostate cancer	8.08e-05	0.000489	CcSEcCtD
Dexmedetomidine—Arrhythmia—Docetaxel—prostate cancer	8.04e-05	0.000487	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Epirubicin—prostate cancer	7.99e-05	0.000484	CcSEcCtD
Dexmedetomidine—Vomiting—Goserelin—prostate cancer	7.97e-05	0.000482	CcSEcCtD
Dexmedetomidine—Pain—Mitoxantrone—prostate cancer	7.91e-05	0.000479	CcSEcCtD
Dexmedetomidine—Constipation—Mitoxantrone—prostate cancer	7.91e-05	0.000479	CcSEcCtD
Dexmedetomidine—Angiopathy—Capecitabine—prostate cancer	7.91e-05	0.000479	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Epirubicin—prostate cancer	7.91e-05	0.000479	CcSEcCtD
Dexmedetomidine—Bradycardia—Prednisone—prostate cancer	7.91e-05	0.000479	CcSEcCtD
Dexmedetomidine—Rash—Goserelin—prostate cancer	7.9e-05	0.000478	CcSEcCtD
Dexmedetomidine—Dermatitis—Goserelin—prostate cancer	7.89e-05	0.000478	CcSEcCtD
Dexmedetomidine—Vomiting—Conjugated Estrogens—prostate cancer	7.89e-05	0.000478	CcSEcCtD
Dexmedetomidine—Mental disorder—Docetaxel—prostate cancer	7.89e-05	0.000478	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Capecitabine—prostate cancer	7.86e-05	0.000476	CcSEcCtD
Dexmedetomidine—Abdominal pain—Estradiol—prostate cancer	7.85e-05	0.000475	CcSEcCtD
Dexmedetomidine—Body temperature increased—Estradiol—prostate cancer	7.85e-05	0.000475	CcSEcCtD
Dexmedetomidine—Headache—Goserelin—prostate cancer	7.85e-05	0.000475	CcSEcCtD
Dexmedetomidine—Malnutrition—Docetaxel—prostate cancer	7.84e-05	0.000475	CcSEcCtD
Dexmedetomidine—Rash—Conjugated Estrogens—prostate cancer	7.82e-05	0.000474	CcSEcCtD
Dexmedetomidine—Chills—Capecitabine—prostate cancer	7.82e-05	0.000474	CcSEcCtD
Dexmedetomidine—Dermatitis—Conjugated Estrogens—prostate cancer	7.82e-05	0.000473	CcSEcCtD
Dexmedetomidine—Haemoglobin—Prednisone—prostate cancer	7.8e-05	0.000473	CcSEcCtD
Dexmedetomidine—Arrhythmia—Capecitabine—prostate cancer	7.79e-05	0.000472	CcSEcCtD
Dexmedetomidine—Headache—Conjugated Estrogens—prostate cancer	7.77e-05	0.000471	CcSEcCtD
Dexmedetomidine—Haemorrhage—Prednisone—prostate cancer	7.77e-05	0.00047	CcSEcCtD
Dexmedetomidine—Confusional state—Etoposide—prostate cancer	7.76e-05	0.00047	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Epirubicin—prostate cancer	7.74e-05	0.000469	CcSEcCtD
Dexmedetomidine—Hallucination—Prednisone—prostate cancer	7.73e-05	0.000468	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—prostate cancer	7.72e-05	0.000468	CcSEcCtD
Dexmedetomidine—Infection—Etoposide—prostate cancer	7.65e-05	0.000463	CcSEcCtD
Dexmedetomidine—Abdominal distension—Epirubicin—prostate cancer	7.64e-05	0.000462	CcSEcCtD
Dexmedetomidine—Mental disorder—Capecitabine—prostate cancer	7.64e-05	0.000462	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Mitoxantrone—prostate cancer	7.63e-05	0.000462	CcSEcCtD
Dexmedetomidine—Malnutrition—Capecitabine—prostate cancer	7.59e-05	0.000459	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Mitoxantrone—prostate cancer	7.57e-05	0.000458	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Etoposide—prostate cancer	7.54e-05	0.000456	CcSEcCtD
Dexmedetomidine—Tachycardia—Etoposide—prostate cancer	7.51e-05	0.000455	CcSEcCtD
Dexmedetomidine—Nausea—Goserelin—prostate cancer	7.44e-05	0.000451	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Etoposide—prostate cancer	7.44e-05	0.000451	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—prostate cancer	7.39e-05	0.000448	CcSEcCtD
Dexmedetomidine—Nausea—Conjugated Estrogens—prostate cancer	7.37e-05	0.000446	CcSEcCtD
Dexmedetomidine—Body temperature increased—Mitoxantrone—prostate cancer	7.32e-05	0.000443	CcSEcCtD
Dexmedetomidine—Abdominal pain—Mitoxantrone—prostate cancer	7.32e-05	0.000443	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	7.31e-05	0.000443	CcSEcCtD
Dexmedetomidine—Anaemia—Docetaxel—prostate cancer	7.24e-05	0.000439	CcSEcCtD
Dexmedetomidine—Hypotension—Etoposide—prostate cancer	7.19e-05	0.000436	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—prostate cancer	7.16e-05	0.000434	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—prostate cancer	7.07e-05	0.000428	CcSEcCtD
Dexmedetomidine—Angiopathy—Prednisone—prostate cancer	7.05e-05	0.000427	CcSEcCtD
Dexmedetomidine—Anaemia—Capecitabine—prostate cancer	7.01e-05	0.000425	CcSEcCtD
Dexmedetomidine—Arrhythmia—Prednisone—prostate cancer	6.94e-05	0.00042	CcSEcCtD
Dexmedetomidine—Dyspnoea—Etoposide—prostate cancer	6.86e-05	0.000416	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Epirubicin—prostate cancer	6.84e-05	0.000414	CcSEcCtD
Dexmedetomidine—Somnolence—Etoposide—prostate cancer	6.84e-05	0.000414	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—prostate cancer	6.8e-05	0.000412	CcSEcCtD
Dexmedetomidine—Mental disorder—Prednisone—prostate cancer	6.8e-05	0.000412	CcSEcCtD
Dexmedetomidine—Diarrhoea—Estradiol—prostate cancer	6.8e-05	0.000411	CcSEcCtD
Dexmedetomidine—Convulsion—Docetaxel—prostate cancer	6.79e-05	0.000411	CcSEcCtD
Dexmedetomidine—Hypertension—Docetaxel—prostate cancer	6.77e-05	0.00041	CcSEcCtD
Dexmedetomidine—Malnutrition—Prednisone—prostate cancer	6.76e-05	0.000409	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Etoposide—prostate cancer	6.65e-05	0.000402	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—prostate cancer	6.63e-05	0.000402	CcSEcCtD
Dexmedetomidine—Pain—Etoposide—prostate cancer	6.58e-05	0.000399	CcSEcCtD
Dexmedetomidine—Constipation—Etoposide—prostate cancer	6.58e-05	0.000399	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—prostate cancer	6.58e-05	0.000398	CcSEcCtD
Dexmedetomidine—Dizziness—Estradiol—prostate cancer	6.57e-05	0.000398	CcSEcCtD
Dexmedetomidine—Hypertension—Capecitabine—prostate cancer	6.55e-05	0.000397	CcSEcCtD
Dexmedetomidine—Dry mouth—Docetaxel—prostate cancer	6.53e-05	0.000395	CcSEcCtD
Dexmedetomidine—Confusional state—Docetaxel—prostate cancer	6.45e-05	0.000391	CcSEcCtD
Dexmedetomidine—Anxiety—Capecitabine—prostate cancer	6.44e-05	0.00039	CcSEcCtD
Dexmedetomidine—Infection—Docetaxel—prostate cancer	6.36e-05	0.000385	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Etoposide—prostate cancer	6.34e-05	0.000384	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—prostate cancer	6.33e-05	0.000383	CcSEcCtD
Dexmedetomidine—Diarrhoea—Mitoxantrone—prostate cancer	6.33e-05	0.000383	CcSEcCtD
Dexmedetomidine—Dry mouth—Capecitabine—prostate cancer	6.32e-05	0.000383	CcSEcCtD
Dexmedetomidine—Vomiting—Estradiol—prostate cancer	6.31e-05	0.000382	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—prostate cancer	6.3e-05	0.000381	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Etoposide—prostate cancer	6.29e-05	0.000381	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Docetaxel—prostate cancer	6.26e-05	0.000379	CcSEcCtD
Dexmedetomidine—Rash—Estradiol—prostate cancer	6.26e-05	0.000379	CcSEcCtD
Dexmedetomidine—Dermatitis—Estradiol—prostate cancer	6.26e-05	0.000379	CcSEcCtD
Dexmedetomidine—Anaemia—Prednisone—prostate cancer	6.25e-05	0.000378	CcSEcCtD
Dexmedetomidine—Confusional state—Capecitabine—prostate cancer	6.25e-05	0.000378	CcSEcCtD
Dexmedetomidine—Tachycardia—Docetaxel—prostate cancer	6.24e-05	0.000378	CcSEcCtD
Dexmedetomidine—Headache—Estradiol—prostate cancer	6.22e-05	0.000377	CcSEcCtD
Dexmedetomidine—Agitation—Prednisone—prostate cancer	6.21e-05	0.000376	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—prostate cancer	6.18e-05	0.000374	CcSEcCtD
Dexmedetomidine—Infection—Capecitabine—prostate cancer	6.15e-05	0.000373	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—prostate cancer	6.14e-05	0.000372	CcSEcCtD
Dexmedetomidine—Haemoglobin—Epirubicin—prostate cancer	6.1e-05	0.00037	CcSEcCtD
Dexmedetomidine—Abdominal pain—Etoposide—prostate cancer	6.09e-05	0.000368	CcSEcCtD
Dexmedetomidine—Body temperature increased—Etoposide—prostate cancer	6.09e-05	0.000368	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—prostate cancer	6.08e-05	0.000368	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—prostate cancer	6.07e-05	0.000368	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Capecitabine—prostate cancer	6.06e-05	0.000367	CcSEcCtD
Dexmedetomidine—Tachycardia—Capecitabine—prostate cancer	6.04e-05	0.000366	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Capecitabine—prostate cancer	5.99e-05	0.000363	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—prostate cancer	5.98e-05	0.000362	CcSEcCtD
Dexmedetomidine—Hypotension—Docetaxel—prostate cancer	5.98e-05	0.000362	CcSEcCtD
Dexmedetomidine—Nausea—Estradiol—prostate cancer	5.9e-05	0.000357	CcSEcCtD
Dexmedetomidine—Vomiting—Mitoxantrone—prostate cancer	5.88e-05	0.000356	CcSEcCtD
Dexmedetomidine—Convulsion—Prednisone—prostate cancer	5.86e-05	0.000355	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—prostate cancer	5.85e-05	0.000354	CcSEcCtD
Dexmedetomidine—Hypertension—Prednisone—prostate cancer	5.84e-05	0.000353	CcSEcCtD
Dexmedetomidine—Rash—Mitoxantrone—prostate cancer	5.83e-05	0.000353	CcSEcCtD
Dexmedetomidine—Dermatitis—Mitoxantrone—prostate cancer	5.83e-05	0.000353	CcSEcCtD
Dexmedetomidine—Headache—Mitoxantrone—prostate cancer	5.8e-05	0.000351	CcSEcCtD
Dexmedetomidine—Hypotension—Capecitabine—prostate cancer	5.79e-05	0.00035	CcSEcCtD
Dexmedetomidine—Anxiety—Prednisone—prostate cancer	5.74e-05	0.000347	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—prostate cancer	5.72e-05	0.000346	CcSEcCtD
Dexmedetomidine—Dyspnoea—Docetaxel—prostate cancer	5.7e-05	0.000345	CcSEcCtD
Dexmedetomidine—Somnolence—Docetaxel—prostate cancer	5.69e-05	0.000344	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—prostate cancer	5.65e-05	0.000342	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—prostate cancer	5.64e-05	0.000341	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—prostate cancer	5.62e-05	0.00034	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—prostate cancer	5.54e-05	0.000335	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Docetaxel—prostate cancer	5.52e-05	0.000334	CcSEcCtD
Dexmedetomidine—Dyspnoea—Capecitabine—prostate cancer	5.52e-05	0.000334	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—prostate cancer	5.51e-05	0.000334	CcSEcCtD
Dexmedetomidine—Nausea—Mitoxantrone—prostate cancer	5.5e-05	0.000333	CcSEcCtD
Dexmedetomidine—Infection—Prednisone—prostate cancer	5.48e-05	0.000332	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—prostate cancer	5.47e-05	0.000331	CcSEcCtD
Dexmedetomidine—Constipation—Docetaxel—prostate cancer	5.47e-05	0.000331	CcSEcCtD
Dexmedetomidine—Pain—Docetaxel—prostate cancer	5.47e-05	0.000331	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—prostate cancer	5.45e-05	0.00033	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—prostate cancer	5.43e-05	0.000329	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—prostate cancer	5.42e-05	0.000328	CcSEcCtD
Dexmedetomidine—Tachycardia—Prednisone—prostate cancer	5.38e-05	0.000326	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Capecitabine—prostate cancer	5.35e-05	0.000324	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Prednisone—prostate cancer	5.33e-05	0.000323	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—prostate cancer	5.32e-05	0.000322	CcSEcCtD
Dexmedetomidine—Pain—Capecitabine—prostate cancer	5.3e-05	0.000321	CcSEcCtD
Dexmedetomidine—Constipation—Capecitabine—prostate cancer	5.3e-05	0.000321	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—prostate cancer	5.29e-05	0.00032	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Docetaxel—prostate cancer	5.27e-05	0.000319	CcSEcCtD
Dexmedetomidine—Diarrhoea—Etoposide—prostate cancer	5.27e-05	0.000319	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Docetaxel—prostate cancer	5.23e-05	0.000317	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—prostate cancer	5.22e-05	0.000316	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Capecitabine—prostate cancer	5.1e-05	0.000309	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—prostate cancer	5.1e-05	0.000309	CcSEcCtD
Dexmedetomidine—Dizziness—Etoposide—prostate cancer	5.09e-05	0.000308	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Capecitabine—prostate cancer	5.06e-05	0.000307	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—prostate cancer	5.06e-05	0.000307	CcSEcCtD
Dexmedetomidine—Abdominal pain—Docetaxel—prostate cancer	5.06e-05	0.000306	CcSEcCtD
Dexmedetomidine—Body temperature increased—Docetaxel—prostate cancer	5.06e-05	0.000306	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—prostate cancer	5.04e-05	0.000305	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—prostate cancer	5.02e-05	0.000304	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—prostate cancer	4.92e-05	0.000298	CcSEcCtD
Dexmedetomidine—Abdominal pain—Capecitabine—prostate cancer	4.9e-05	0.000296	CcSEcCtD
Dexmedetomidine—Body temperature increased—Capecitabine—prostate cancer	4.9e-05	0.000296	CcSEcCtD
Dexmedetomidine—Vomiting—Etoposide—prostate cancer	4.89e-05	0.000296	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—prostate cancer	4.89e-05	0.000296	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—prostate cancer	4.89e-05	0.000296	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—prostate cancer	4.86e-05	0.000294	CcSEcCtD
Dexmedetomidine—Rash—Etoposide—prostate cancer	4.85e-05	0.000294	CcSEcCtD
Dexmedetomidine—Dermatitis—Etoposide—prostate cancer	4.85e-05	0.000294	CcSEcCtD
Dexmedetomidine—Headache—Etoposide—prostate cancer	4.82e-05	0.000292	CcSEcCtD
Dexmedetomidine—Constipation—Prednisone—prostate cancer	4.72e-05	0.000286	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—prostate cancer	4.58e-05	0.000277	CcSEcCtD
Dexmedetomidine—Nausea—Etoposide—prostate cancer	4.57e-05	0.000277	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—prostate cancer	4.56e-05	0.000276	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Prednisone—prostate cancer	4.55e-05	0.000275	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—prostate cancer	4.52e-05	0.000274	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Prednisone—prostate cancer	4.51e-05	0.000273	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—prostate cancer	4.5e-05	0.000272	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—prostate cancer	4.49e-05	0.000272	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—prostate cancer	4.4e-05	0.000267	CcSEcCtD
Dexmedetomidine—Diarrhoea—Docetaxel—prostate cancer	4.38e-05	0.000265	CcSEcCtD
Dexmedetomidine—Body temperature increased—Prednisone—prostate cancer	4.36e-05	0.000264	CcSEcCtD
Dexmedetomidine—Abdominal pain—Prednisone—prostate cancer	4.36e-05	0.000264	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—prostate cancer	4.35e-05	0.000263	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—prostate cancer	4.29e-05	0.00026	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—prostate cancer	4.24e-05	0.000257	CcSEcCtD
Dexmedetomidine—Diarrhoea—Capecitabine—prostate cancer	4.24e-05	0.000257	CcSEcCtD
Dexmedetomidine—Dizziness—Docetaxel—prostate cancer	4.23e-05	0.000256	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—prostate cancer	4.22e-05	0.000256	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—prostate cancer	4.22e-05	0.000256	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—prostate cancer	4.21e-05	0.000255	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—prostate cancer	4.17e-05	0.000253	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—prostate cancer	4.15e-05	0.000251	CcSEcCtD
Dexmedetomidine—Dizziness—Capecitabine—prostate cancer	4.1e-05	0.000248	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—prostate cancer	4.07e-05	0.000247	CcSEcCtD
Dexmedetomidine—Vomiting—Docetaxel—prostate cancer	4.07e-05	0.000246	CcSEcCtD
Dexmedetomidine—Rash—Docetaxel—prostate cancer	4.03e-05	0.000244	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—prostate cancer	4.03e-05	0.000244	CcSEcCtD
Dexmedetomidine—Dermatitis—Docetaxel—prostate cancer	4.03e-05	0.000244	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—prostate cancer	4.03e-05	0.000244	CcSEcCtD
Dexmedetomidine—Headache—Docetaxel—prostate cancer	4.01e-05	0.000243	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—prostate cancer	3.97e-05	0.00024	CcSEcCtD
Dexmedetomidine—Vomiting—Capecitabine—prostate cancer	3.94e-05	0.000238	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—prostate cancer	3.91e-05	0.000237	CcSEcCtD
Dexmedetomidine—Rash—Capecitabine—prostate cancer	3.91e-05	0.000236	CcSEcCtD
Dexmedetomidine—Dermatitis—Capecitabine—prostate cancer	3.9e-05	0.000236	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—prostate cancer	3.9e-05	0.000236	CcSEcCtD
Dexmedetomidine—Headache—Capecitabine—prostate cancer	3.88e-05	0.000235	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—prostate cancer	3.86e-05	0.000234	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—prostate cancer	3.85e-05	0.000233	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—prostate cancer	3.84e-05	0.000232	CcSEcCtD
Dexmedetomidine—Nausea—Docetaxel—prostate cancer	3.8e-05	0.00023	CcSEcCtD
Dexmedetomidine—Diarrhoea—Prednisone—prostate cancer	3.77e-05	0.000229	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—prostate cancer	3.73e-05	0.000226	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—prostate cancer	3.73e-05	0.000226	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—prostate cancer	3.69e-05	0.000223	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—prostate cancer	3.69e-05	0.000223	CcSEcCtD
Dexmedetomidine—Nausea—Capecitabine—prostate cancer	3.68e-05	0.000223	CcSEcCtD
Dexmedetomidine—Dizziness—Prednisone—prostate cancer	3.65e-05	0.000221	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—prostate cancer	3.56e-05	0.000216	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—prostate cancer	3.56e-05	0.000215	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—prostate cancer	3.55e-05	0.000215	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—prostate cancer	3.53e-05	0.000214	CcSEcCtD
Dexmedetomidine—Vomiting—Prednisone—prostate cancer	3.51e-05	0.000212	CcSEcCtD
Dexmedetomidine—Rash—Prednisone—prostate cancer	3.48e-05	0.000211	CcSEcCtD
Dexmedetomidine—Dermatitis—Prednisone—prostate cancer	3.48e-05	0.00021	CcSEcCtD
Dexmedetomidine—Headache—Prednisone—prostate cancer	3.46e-05	0.000209	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.45e-05	0.000209	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—prostate cancer	3.41e-05	0.000207	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—prostate cancer	3.41e-05	0.000207	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—prostate cancer	3.41e-05	0.000207	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—prostate cancer	3.41e-05	0.000207	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—prostate cancer	3.29e-05	0.000199	CcSEcCtD
Dexmedetomidine—Nausea—Prednisone—prostate cancer	3.28e-05	0.000198	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—prostate cancer	3.26e-05	0.000198	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—prostate cancer	3.16e-05	0.000191	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—prostate cancer	3.16e-05	0.000191	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—prostate cancer	2.95e-05	0.000179	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—prostate cancer	2.85e-05	0.000173	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—prostate cancer	2.74e-05	0.000166	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—prostate cancer	2.73e-05	0.000165	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—prostate cancer	2.72e-05	0.000165	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—prostate cancer	2.72e-05	0.000165	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—prostate cancer	2.7e-05	0.000164	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—prostate cancer	2.64e-05	0.00016	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—prostate cancer	2.56e-05	0.000155	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—prostate cancer	2.54e-05	0.000154	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—prostate cancer	2.52e-05	0.000152	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—prostate cancer	2.51e-05	0.000152	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—prostate cancer	2.5e-05	0.000151	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—prostate cancer	2.37e-05	0.000144	CcSEcCtD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—prostate cancer	2.82e-06	2.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	2.81e-06	2.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	2.81e-06	2.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	2.81e-06	2.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	2.79e-06	2.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JAK2—prostate cancer	2.79e-06	2.57e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TYMS—prostate cancer	2.78e-06	2.57e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NCOA1—prostate cancer	2.78e-06	2.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	2.78e-06	2.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	2.77e-06	2.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	2.77e-06	2.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	2.76e-06	2.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—prostate cancer	2.76e-06	2.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1B—prostate cancer	2.75e-06	2.54e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—prostate cancer	2.75e-06	2.54e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP19A1—prostate cancer	2.74e-06	2.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	2.73e-06	2.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	2.73e-06	2.52e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—INS—prostate cancer	2.73e-06	2.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—prostate cancer	2.72e-06	2.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MDM2—prostate cancer	2.72e-06	2.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGF2—prostate cancer	2.72e-06	2.51e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—prostate cancer	2.71e-06	2.5e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BAD—prostate cancer	2.71e-06	2.5e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—LPL—prostate cancer	2.7e-06	2.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—prostate cancer	2.7e-06	2.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—prostate cancer	2.69e-06	2.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	2.68e-06	2.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—prostate cancer	2.68e-06	2.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NOS3—prostate cancer	2.68e-06	2.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGF2—prostate cancer	2.67e-06	2.47e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CREBBP—prostate cancer	2.67e-06	2.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	2.65e-06	2.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—RXRA—prostate cancer	2.65e-06	2.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NOS3—prostate cancer	2.64e-06	2.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—prostate cancer	2.63e-06	2.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	2.62e-06	2.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—APC—prostate cancer	2.62e-06	2.42e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.61e-06	2.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JAK2—prostate cancer	2.6e-06	2.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NOS3—prostate cancer	2.6e-06	2.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	2.6e-06	2.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	2.59e-06	2.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGF—prostate cancer	2.59e-06	2.39e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ERCC2—prostate cancer	2.59e-06	2.39e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.57e-06	2.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—INS—prostate cancer	2.57e-06	2.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JAK2—prostate cancer	2.56e-06	2.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—prostate cancer	2.56e-06	2.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	2.55e-06	2.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—prostate cancer	2.55e-06	2.35e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—COMT—prostate cancer	2.55e-06	2.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	2.54e-06	2.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MDM2—prostate cancer	2.54e-06	2.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	2.54e-06	2.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—prostate cancer	2.54e-06	2.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—prostate cancer	2.53e-06	2.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—prostate cancer	2.53e-06	2.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CREBBP—prostate cancer	2.52e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	2.52e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	2.51e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	2.51e-06	2.31e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MDM2—prostate cancer	2.5e-06	2.31e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ITPR1—prostate cancer	2.5e-06	2.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	2.48e-06	2.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—INS—prostate cancer	2.48e-06	2.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	2.47e-06	2.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	2.47e-06	2.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	2.47e-06	2.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	2.46e-06	2.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.45e-06	2.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—EP300—prostate cancer	2.44e-06	2.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—prostate cancer	2.44e-06	2.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	2.43e-06	2.25e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—prostate cancer	2.43e-06	2.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—prostate cancer	2.43e-06	2.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	2.43e-06	2.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—prostate cancer	2.42e-06	2.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EP300—prostate cancer	2.42e-06	2.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—prostate cancer	2.4e-06	2.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	2.4e-06	2.21e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NOS3—prostate cancer	2.39e-06	2.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	2.39e-06	2.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—prostate cancer	2.39e-06	2.2e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARA—prostate cancer	2.39e-06	2.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—prostate cancer	2.38e-06	2.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	2.38e-06	2.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—prostate cancer	2.37e-06	2.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMS—prostate cancer	2.36e-06	2.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SRC—prostate cancer	2.35e-06	2.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	2.35e-06	2.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	2.34e-06	2.16e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—prostate cancer	2.33e-06	2.15e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	2.32e-06	2.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	2.32e-06	2.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	2.3e-06	2.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	2.3e-06	2.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	2.3e-06	2.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	2.29e-06	2.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	2.29e-06	2.11e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—LPL—prostate cancer	2.29e-06	2.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	2.29e-06	2.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	2.28e-06	2.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	2.28e-06	2.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	2.28e-06	2.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	2.27e-06	2.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—prostate cancer	2.27e-06	2.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—prostate cancer	2.27e-06	2.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	2.26e-06	2.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	2.26e-06	2.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	2.26e-06	2.08e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NOS3—prostate cancer	2.25e-06	2.08e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CAV1—prostate cancer	2.24e-06	2.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	2.24e-06	2.07e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—prostate cancer	2.24e-06	2.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	2.23e-06	2.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	2.22e-06	2.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	2.21e-06	2.04e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.21e-06	2.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	2.21e-06	2.04e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—prostate cancer	2.21e-06	2.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ERCC2—prostate cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—prostate cancer	2.19e-06	2.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EP300—prostate cancer	2.18e-06	2.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	2.18e-06	2.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	2.18e-06	2.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	2.16e-06	1.99e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	2.15e-06	1.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	2.14e-06	1.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	2.14e-06	1.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SRC—prostate cancer	2.12e-06	1.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	2.12e-06	1.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	2.12e-06	1.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	2.11e-06	1.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—prostate cancer	2.11e-06	1.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	2.1e-06	1.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	2.1e-06	1.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	2.08e-06	1.92e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—prostate cancer	2.08e-06	1.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—prostate cancer	2.08e-06	1.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.07e-06	1.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	2.07e-06	1.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	2.06e-06	1.9e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—prostate cancer	2.06e-06	1.9e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—prostate cancer	2.06e-06	1.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—prostate cancer	2.06e-06	1.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	2.05e-06	1.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	2.05e-06	1.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.04e-06	1.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EP300—prostate cancer	2.04e-06	1.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	2.04e-06	1.88e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARA—prostate cancer	2.02e-06	1.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	2.01e-06	1.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EP300—prostate cancer	2.01e-06	1.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SRC—prostate cancer	1.98e-06	1.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—EP300—prostate cancer	1.98e-06	1.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SRC—prostate cancer	1.95e-06	1.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—prostate cancer	1.95e-06	1.8e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—INS—prostate cancer	1.93e-06	1.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	1.93e-06	1.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	1.93e-06	1.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	1.91e-06	1.76e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—prostate cancer	1.91e-06	1.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—prostate cancer	1.9e-06	1.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CAV1—prostate cancer	1.9e-06	1.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.9e-06	1.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	1.9e-06	1.75e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CREBBP—prostate cancer	1.89e-06	1.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.89e-06	1.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.88e-06	1.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.86e-06	1.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	1.86e-06	1.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.85e-06	1.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.84e-06	1.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.84e-06	1.69e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—EP300—prostate cancer	1.82e-06	1.68e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.82e-06	1.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—prostate cancer	1.8e-06	1.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.8e-06	1.66e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—prostate cancer	1.8e-06	1.66e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.8e-06	1.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	1.79e-06	1.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.78e-06	1.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—prostate cancer	1.78e-06	1.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	1.77e-06	1.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	1.76e-06	1.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—prostate cancer	1.75e-06	1.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	1.75e-06	1.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	1.74e-06	1.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.74e-06	1.61e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	1.74e-06	1.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.74e-06	1.6e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.73e-06	1.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—prostate cancer	1.73e-06	1.6e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—EP300—prostate cancer	1.71e-06	1.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	1.71e-06	1.58e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NOS3—prostate cancer	1.7e-06	1.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	1.69e-06	1.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.66e-06	1.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	1.64e-06	1.51e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—INS—prostate cancer	1.64e-06	1.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	1.62e-06	1.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	1.61e-06	1.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.61e-06	1.49e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CREBBP—prostate cancer	1.6e-06	1.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—prostate cancer	1.58e-06	1.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.57e-06	1.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.57e-06	1.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—prostate cancer	1.56e-06	1.44e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.55e-06	1.43e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.55e-06	1.43e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.52e-06	1.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	1.51e-06	1.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	1.48e-06	1.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—prostate cancer	1.47e-06	1.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.46e-06	1.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—prostate cancer	1.46e-06	1.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—prostate cancer	1.46e-06	1.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NOS3—prostate cancer	1.44e-06	1.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—prostate cancer	1.44e-06	1.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—prostate cancer	1.43e-06	1.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.41e-06	1.3e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—prostate cancer	1.35e-06	1.25e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—prostate cancer	1.34e-06	1.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—prostate cancer	1.34e-06	1.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.33e-06	1.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.33e-06	1.22e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	1.32e-06	1.22e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—prostate cancer	1.31e-06	1.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—prostate cancer	1.31e-06	1.21e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—EP300—prostate cancer	1.29e-06	1.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—prostate cancer	1.27e-06	1.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	1.23e-06	1.14e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.22e-06	1.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	1.21e-06	1.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—prostate cancer	1.2e-06	1.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.18e-06	1.09e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—prostate cancer	1.15e-06	1.06e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—prostate cancer	1.1e-06	1.01e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—EP300—prostate cancer	1.09e-06	1.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.08e-06	1e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—prostate cancer	1.04e-06	9.56e-06	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1e-06	9.23e-06	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—prostate cancer	9.54e-07	8.8e-06	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—prostate cancer	8.08e-07	7.46e-06	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—prostate cancer	7.8e-07	7.19e-06	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—prostate cancer	6.6e-07	6.09e-06	CbGpPWpGaD
